PALM INTRANET

Day : Thursday
Date: 2/15/2007

Time: 13:32:41

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	**First Name**	
Ewing	Gary	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Thursday
Date: 2/15/2007

Time: 13:32:41

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Sperry	David	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Thursday
Date: 2/15/2007

Time: 12:51:24

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	**First Name**	
Gao	Ping	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Thursday
Date: 2/15/2007

Time: 13:17:14

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	**First Name**	
Bauer	Juliane	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

Freeform Search

Database: US Pre-Grant Publication Full-Text Database; **US Patents Full-Text Database**; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: L41 and (soft near8 "gelatin capsule")

Display: 20 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Side by Side ○ Image

Search | Clear | Interrupt

Search History

DATE: Thursday, February 15, 2007 Purge Queries Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L42	L41 and (soft near8 "gelatin capsule")	66	L42
L41	L40 and (surfactant or "polysorbate 80")	278	L41
L40	L39 and (antioxidant or "anti-oxidant")	392	L40
L39	L38 and water	684	L39
L38	L36 and (PEG or "polyethyleneglycol" or "polyethylene glycol")	686	L38
L37	L36 and ("free-radical" near scaveng$4)	2	L37
L36	L35 same (liquid or "fill material" or fill)	1054	L36
L35	(capsule or bolus or cap or dose or lozenge or pellet or pill or troche) same ("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid" or "disodium metabisulfite" or "sodium pyrosulfite" or "sodium pyrosulphite" or metabisulfite or metabisulphite or pyrosulfite or pyrosulfite) (capsule or bolus or cap or dose or lozenge or pellet or pill or troche) and ("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium	6065	L35

L34	disulfite" or "disulfurous acid" or "disodium metabisulfite" or "sodium pyrosulfite" or "sodium pyrosulphite" or metabisulfite or metabisulphite or pyrosulfite or pyrosulfite)	32315	L34
L33	L32 and (capsule same liquid)	609	L33
L32	L30 and @pd<20011004	987	L32
L31	L30 and (("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid" or "disodium metabisulfite" or "sodium pyrosulfite" or "sodium pyrosulphite" or metabisulfite or metabisulphite or pyrosulfite or pyrosulfite) near8 capsule)	7	L31
L30	L29 and capsule	6035	L30
L29	L27 and ("cross-linked" or denatur$7 or (cross near3 link$4))	14748	L29
L28	L27 and (capusle same ("cross-linked" or denatur$7 or (cross near3 link$4)))	0	L28
L27	("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid" or "disodium metabisulfite" or "sodium pyrosulfite" or "sodium pyrosulphite" or metabisulfite or metabisulphite or pyrosulfite or pyrosulfite)	70809	L27
L26	L24 and "cross-link"	18	L26
L25	L24 and ((sulfite or sulphite) near8 "cross-link$4")	0	L25
L24	L23 and (pharmaceutical same capsule)	530	L24
L23	L21 and pharmaceutical	747	L23
L22	L21 and (("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid") near6 capsule)	34	L22
L21	L14 same capsule	914	L21
L20	L19 and (sulfite same capsule)	25	L20
L19	L17 and oral	1166	L19
L18	(L14 and L13) same capsule	3	L18
L17	L15 and capsule	1186	L17
L16	L14 same L13	13	L16
L15	L14 and L13	1301	L15
L14	("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid")	68023	L14
L13	(celecoxib or ("COX-2" near5 inhibitor$3) or "4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzensulfonamide" or "SC 58635" or celebrex or "cyclooxygenase inhibitor")	9165	L13
	DB=USPT; PLUR=YES; OP=OR		
L12	(5733909 or 5874106 or 6214378 or 6214378).pn.	3	L12
	DB=DWPI; PLUR=YES; OP=OR		
L11	EP0695544.pn.	0	L11
	DB=PGPB,USPT; PLUR=YES; OP=OR		
L10	L9 and "cyclooxygenase-2"	14	L10

L9	L4 and capsule	41	L9
L8	L7 and capsule	1	L8
L7	David near4 Sperry	5	L7
L6	Gary near4 Ewing	13	L6
L5	Juliane near4 Bauer	4	L5
L4	Ping near Gao	57	L4
DB=PGPB; PLUR=YES; OP=OR			
L3	20040105884.pn.	1	L3
DB=USPT; PLUR=YES; OP=OR			
L2	6231887.pn.	1	L2
L1	6579895.pn.	1	L1

END OF SEARCH HISTORY

National Library of Medicine - Medical Subject Headings

2007 MeSH

MeSH Supplementary Concept Data

Return to Entry Page

Name of Substance	celecoxib
Record Type	C
Registry Number	169590-42-5
Entry Term	4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
Entry Term	Celebrex
Entry Term	Heumann brand of celecoxib
Entry Term	Mack brand of celecoxib
Entry Term	Parke Davis brand of celecoxib
Entry Term	Pfizer brand of celecoxib
Entry Term	Pharmacia Spain brand of celecoxib
Entry Term	Pharmacia brand of celecoxib
Entry Term	SC 58635
Entry Term	SC-58635
Entry Term	Searle brand of celecoxib
Heading Mapped to	*Pyrazoles
Heading Mapped to	*Sulfonamides
Indexing Information	Cardiovascular Diseases
Source	J Med Chem 1997 Apr 25;40(9):1347-65
Pharm. Action	Anti-Inflammatory Agents, Non-Steroidal
Pharm. Action	Cyclooxygenase Inhibitors
Frequency	1609
Note	inhibits COX-2 more than COX-1; structure in first source; cardiovascular risk found in long term cancer trial
Date of Entry	19970603
Revision Date	20041229
Unique ID	C105934

Return to Entry Page **Link to NLM Cataloging Classification**

```
     (FILE 'HOME' ENTERED AT 18:04:15 ON 15 FEB 2007)

     FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 18:04:28 ON 15 FEB 2007
L1        66564 S ((SODIUM (3A) (METABISULFITE OR BISULFITE OR THIOSULFATE OR M

     FILE 'REGISTRY' ENTERED AT 18:23:25 ON 15 FEB 2007
L2            6 S CELECOXIB

     FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 18:23:50 ON 15 FEB 2007
L3         4601 S L2
L4            0 S L3 (P) L1
L5          102 S L3 AND L1
L6           77 S L5 AND (CAPSULE OR PILL OR TROCHE OR LOZENGE OR TROCHE)
L7           75 S L6 AND CAPSULE
L8           24 S L7 AND (CAPSULE (P) GELATIN?)
L9           20 DUPLICATE REMOVE L8 (4 DUPLICATES REMOVED)
L10          20 FOCUS L9 1-

     FILE 'STNGUIDE' ENTERED AT 18:29:21 ON 15 FEB 2007

     FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 18:34:14 ON 15 FEB 2007
L11       13759 S ((CYCLOOXYGENASE(2A)2)(8A)INHIBIT?)
L12           4 S L11 (P) L1
L13           4 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)

     FILE 'STNGUIDE' ENTERED AT 18:36:55 ON 15 FEB 2007

     FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 18:38:52 ON 15 FEB 2007
L14         419 S L11 AND L1
L15         258 S L14 AND CAPSULE
L16         257 S L15 AND (WATER OR PEG OR (POLYETHYLENE(4A)GLYCOL))
L17          65 S L16 AND (ANTIOXIDANT OR (ANTI(3A)OXIDANT))
L18          23 S L17 AND (SURFACTANT OR POLYSORBATE OR (POLYSORBATE(4A)80))
L19          23 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> d que l1
L1        66564 SEA ((SODIUM (3A) (METABISULFITE OR BISULFITE OR THIOSULFATE
                OR METABISULPHITE OR BISULPHITE OR PYROSULFITE OR DISULFITE))
                OR (DISULFUROUS(W) ACID) OR (DISODIUM(W) METABISULFITE) OR
                (SODIUM(3A)(PYROSULFITE OR PYROSULPHITE OR METABISULFITE OR
                METABISULPHITE)))
```

L10 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pellicle-resistant gelatin capsule
AB The present invention relates to compns. suitable for use in preparing gelatin capsules for pharmaceutical, nutraceutical and food industries, to gelatin capsules exhibiting reduced crosslinking and/or pellicle formation, and to methods of preparing such gelatin capsules. Dosage forms comprising a drug, such as a cyclooxygenase-2 inhibitor are also described. For example, a composition suitable for preparation of a capsule wall contained gelatin 42%, glycerol (85%) 10%, sorbitol 15%, tromethamine 7.5%, and water 25.5%. Filled capsules were stored at 40° and 75% relative humidity for up to 24 wk. Capsules exhibit less pellicle formation than do capsules prepared from comparative composition with no primary amine.

ACCESSION NUMBER: 2004:550544 CAPLUS
DOCUMENT NUMBER: 141:94340
TITLE: Pellicle-resistant gelatin capsule
INVENTOR(S): Gao, Ping
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Pat. Appl. 2003 105,141.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004131670	A1	20040708	US 2003-633102		20030731
US 2003105141	A1	20030605	US 2002-119129		20020409
ZA 2003007575	A	20050103	ZA 2003-7575		20030929
PRIORITY APPLN. INFO.:			US 2001-284381P	P	20010417
			US 2001-326952P	P	20011004
			US 2002-119129	A2	20020409
			US 2002-399776P	P	20020731
			US 2002-399808P	P	20020731
			US 2002-399862P	P	20020731
			US 2002-399863P	P	20020731

OTHER SOURCE(S): MARPAT 141:94340

L10 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pellicle-resistant gelatin capsule
AB The present invention relates to compns. suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced crosslinking, and to methods of preparing such gelatin capsules. The compns. comprise gelatin and an amine agent used for inhibition of crosslinking of the gelatin and/or pellicle formation in a capsule shell. The amine agent is selected from tromethamines, ethanolamine, ethylenediamine, diethylamine, ethylene N-methyl-D-glucamine, amino acids, diethanolamine, benethamine, benzathine, piperazine, hydrabamine, and imidazoles. The compns. further comprise at list one excipient selected from decomposition inhibitors, opacifying agents, preservatives, and plasticizers. Capsules are useful for oral delivery of drugs, e.g., a selective cyclooxygenase-2 inhibitory drugs, such as celecoxib. For example, a capsule wall was prepared from gelatin 40%, 85% glycerol 25%, tromethamine 10%, and water 25%. The capsules were filled and after 24 wk storage at 40° and 75% relative humidity exhibited less pellicle formation than did capsules prepared from comparative composition with no primary amine.

ACCESSION NUMBER: 2004:100974 CAPLUS
DOCUMENT NUMBER: 140:151970
TITLE: Pellicle-resistant gelatin capsule

INVENTOR(S): Gao, Ping
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010972	A2	20040205	WO 2003-US24042	20030731
WO 2004010972	A3	20040729		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494069	A1	20040205	CA 2003-2494069	20030731
AU 2003257981	A1	20040216	AU 2003-257981	20030731
EP 1526844	A2	20050504	EP 2003-772159	20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012875	A	20050628	BR 2003-12875	20030731
JP 2005538993	T	20051222	JP 2004-524261	20030731
PRIORITY APPLN. INFO.:			US 2002-399776P P	20020731
			US 2002-399808P P	20020731
			US 2002-399862P P	20020731
			US 2002-399863P P	20020731
			WO 2003-US24042 W	20030731

OTHER SOURCE(S): MARPAT 140:151970

L10 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gelatin capsule exhibiting reduced cross-linking
AB The present invention relates to compns. suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced crosslinking, and to methods of preparing such gelatin capsules. The compns. comprise gelatin and a sulfite compound used for inhibition of gelatin crosslinking and/or pellicle formation in a capsule shell. The composition further comprises at least one excipient selected from decomposition inhibitors, opacifying agents, preservatives, and plasticizers. Capsules are useful for oral delivery of drugs, e.g., a selective cyclooxygenase-2 inhibitory drugs, such as celecoxib. For example, a capsule wall was prepared from gelatin 42%, 85% glycerol 10%, sorbitol 15%, sodium bisulfite 7.5%, and water 25.5%. The capsules were filled and after a 24 wk storage at 40° and 75% relative humidity exhibited less pellicle formation than did capsules prepared from comparative composition with no bisulfite.
ACCESSION NUMBER: 2004:100976 CAPLUS
DOCUMENT NUMBER: 140:151972
TITLE: Gelatin capsule exhibiting reduced cross-linking
INVENTOR(S): Gao, Ping
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004010974	A2	20040205	WO 2003-US24045		20030731
WO 2004010974	A3	20040805			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2493980	A1	20040205	CA 2003-2493980		20030731
AU 2003257103	A1	20040216	AU 2003-257103		20030731
EP 1526846	A2	20050504	EP 2003-772161		20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013150	A	20050628	BR 2003-13150		20030731
JP 2005538102	T	20051215	JP 2004-524263		20030731
PRIORITY APPLN. INFO.:			US 2002-399776P	P	20020731
			US 2002-399808P	P	20020731
			US 2002-399862P	P	20020731
			US 2002-399863P	P	20020731
			WO 2003-US24045	W	20030731

OTHER SOURCE(S): MARPAT 140:151972

L10 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gelatin capsule exhibiting reduced crosslinking with addition of sulfites
AB The present invention relates to compns. suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced crosslinking, and to methods of preparing such gelatin capsules. Capsules prepared from compns. containing a sulfite such as Na bisulfite or Na metabisulfite exhibit less pellicle formation than do capsules prepared without the sulfites.
ACCESSION NUMBER: 2004:451483 CAPLUS
DOCUMENT NUMBER: 140:429045
TITLE: Gelatin capsule exhibiting reduced crosslinking with addition of sulfites
INVENTOR(S): Gao, Ping
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 119,129.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004105885	A1	20040603	US 2003-633194		20030731
US 2003105141	A1	20030605	US 2002-119129		20020409
ZA 2003007575	A	20050103	ZA 2003-7575		20030929
PRIORITY APPLN. INFO.:			US 2001-284381P	P	20010417
			US 2001-326952P	P	20011004
			US 2002-119129	A2	20020409
			US 2002-399776P	P	20020731
			US 2002-399808P	P	20020731
			US 2002-399862P	P	20020731

US 2002-399863P P 20020731

OTHER SOURCE(S): MARPAT 140:429045

L10 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

TI Pharmaceutical dosage form comprising a sulfite compound

AB The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility and (b) a sulfite compound in an amount sufficient to inhibit crosslinking of gelatin in the gelatin capsule upon storage of the dosage form in a closed container maintained at 40° and 75% relative humidity for a period of 6 mo. For example, a soft capsule was formulated containing celecoxib 270, PEG-400 335, Tween 80 195, oleic acid 78, HPMC 74, DMAE 35, Pr gallate 2, water 7, and Na metabisulfite 4 parts.

ACCESSION NUMBER: 2004:451482 CAPLUS

DOCUMENT NUMBER: 141:12299

TITLE: Pharmaceutical dosage form comprising a sulfite compound

INVENTOR(S): Gao, Ping; Bauer, Juliane M.; Ewing, Gary D.; Sperry, David C.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 119,129.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004105884	A1	20040603	US 2003-632737	20030731
US 2003105141	A1	20030605	US 2002-119129	20020409
ZA 2003007575	A	20050103	ZA 2003-7575	20030929

PRIORITY APPLN. INFO.:

US 2001-284381P	P	20010417
US 2001-326952P	P	20011004
US 2002-119129	A2	20020409
US 2002-399776P	P	20020731
US 2002-399808P	P	20020731
US 2002-399862P	P	20020731
US 2002-399863P	P	20020731

OTHER SOURCE(S): MARPAT 141:12299

L10 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

TI Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage

AB The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule, wherein the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility and (b) a primary or secondary amine compound in an amount sufficient to inhibit crosslinking of gelatin in the gelatin capsule upon storage of the dosage form in a closed container maintained at 40° and 75% relative humidity for a period of 6 mo. For example, a composition containing celecoxib 200, PEG-400 271, Tween-80 217, oleic acid 61, PVP 47, ethanol 113, hydroxypropyl Me cellulose 39, water 26, Pr gallate 1, tromethamine 26 parts were filled into soft gelatin capsules. The capsules exhibited no pellicle formation during storage for a period of 6 mo at 40° and 75% relative humidity.

ACCESSION NUMBER: 2004:451481 CAPLUS

DOCUMENT NUMBER: 141:12298

TITLE: Pharmaceutical dosage form capable of maintaining

stable dissolution profile upon storage
INVENTOR(S): Gao, Ping; Bauer, Juliane M.; He, Xiaorong
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 119,129.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004105883	A1	20040603	US 2003-633390		20030731
US 2003105141	A1	20030605	US 2002-119129		20020409
ZA 2003007575	A	20050103	ZA 2003-7575		20030929
PRIORITY APPLN. INFO.:			US 2001-284381P	P	20010417
			US 2001-326952P	P	20011004
			US 2002-119129	A2	20020409
			US 2002-399776P	P	20020731
			US 2002-399808P	P	20020731
			US 2002-399862P	P	20020731
			US 2002-399863P	P	20020731

OTHER SOURCE(S): MARPAT 141:12298

L10 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gelatin capsules capable of maintaining stable dissolution profile of COX-2 inhibitors upon storage
AB The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a primary or secondary amine compound in an amount sufficient to inhibit crosslinking of gelatin in the capsule upon storage of the dosage form in a closed container maintained at 40° and 75% relative humidity for a period of 6 mo. For example, soft gelatin capsules filled with a formulation containing celecoxib 200 mg, PEG 400 271 mg, Tween 80 217 mg, oleic acid 61 mg, PVP 47 mg, ethanol 113 mg, hydroxypropyl Me cellulose 38 mg, water 25 mg, Pr gallate 1 mg, and tromethamine 26 mg (.apprx. 3%), after a 24 wk storage at 40° and 75% relative humidity, exhibited no pellicle formation. By contrast, capsules containing no amine or 0.5% tromethamine exhibited pellicle formation by 2 and 4 wk of storage, resp.
ACCESSION NUMBER: 2004:100975 CAPLUS
DOCUMENT NUMBER: 140:151971
TITLE: Gelatin capsules capable of maintaining stable dissolution profile of COX-2 inhibitors upon storage
INVENTOR(S): Gao, Ping; Bauer, Juliane M.; He, Xiaorong
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010973	A2	20040205	WO 2003-US24043	20030731
WO 2004010973	A3	20040805		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2494358	A1	20040205	CA 2003-2494358		20030731
AU 2003257982	A1	20040216	AU 2003-257982		20030731
EP 1526845	A2	20050504	EP 2003-772160		20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013149	A	20050628	BR 2003-13149		20030731
JP 2005538994	T	20051222	JP 2004-524262		20030731
PRIORITY APPLN. INFO.:			US 2002-399776P	P	20020731
			US 2002-399808P	P	20020731
			US 2002-399862P	P	20020731
			US 2002-399863P	P	20020731
			WO 2003-US24043	W	20030731

OTHER SOURCE(S): MARPAT 140:151971

L10 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical dosage form comprising a sulfite compound
AB The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a sulfite compound in an amount sufficient to inhibit crosslinking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40°C and 75% relative humidity for a period of 6 mo. Capsules containing celecoxib 278, Tween-80 195, PEG-400 337, oleic acid 80, hydroxypropyl Me cellulose 74, Pr gallate 2, dimethylamino-ethanol 34 35Total 34. Celecoxib capsules containing sodium metabisulfite in an amount of about 3% by weight of the fill material exhibited no pellicle formation during storage for a period of six months, as compared with capsules containing no sulfite compound which exhibited pellicle formation by two weeks of storage.

ACCESSION NUMBER: 2004:220182 CAPLUS
DOCUMENT NUMBER: 140:259114
TITLE: Pharmaceutical dosage form comprising a sulfite compound
INVENTOR(S): Gao, Ping; Bauer, Juliane M.; Ewing, Gary; Sperry, David
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022032	A2	20040318	WO 2003-US24044	20030731
WO 2004022032	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2493974	A1	20040318	CA 2003-2493974		20030731
AU 2003257102	A1	20040329	AU 2003-257102		20030731
EP 1526847	A2	20050504	EP 2003-794452		20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013064	A	20050628	BR 2003-13064		20030731
JP 2006500389	T	20060105	JP 2004-534259		20030731
PRIORITY APPLN. INFO.:			US 2002-399776P	P	20020731
			US 2002-399808P	P	20020731
			US 2002-399862P	P	20020731
			US 2002-399863P	P	20020731
			WO 2003-US24044	W	20030731

OTHER SOURCE(S): MARPAT 140:259114

L13 ANSWER 2 OF 4 USPATFULL on STN
AN 2004:138712 USPATFULL
TI Pharmaceutical dosage form comprising a sulfite compound
IN Gao, Ping, Portage, MI, UNITED STATES
Bauer, Juliane M., Portage, MI, UNITED STATES
Ewing, Gary D., Kalamazoo, MI, UNITED STATES
Sperry, David C., Kalamazoo, MI, UNITED STATES
PI US 2004105884 A1 20040603
AI US 2003-632737 A1 20030731 (10)
RLI Continuation-in-part of Ser. No. US 2002-119129, filed on 9 Apr 2002, PENDING
PRAI US 2001-284381P 20010417 (60)
US 2001-326952P 20011004 (60)
US 2002-399862P 20020731 (60)
US 2002-399776P 20020731 (60)
US 2002-399863P 20020731 (60)
US 2002-399808P 20020731 (60)
DT Utility
FS APPLICATION
LN.CNT 1150
INCL INCLM: 424/456.000
INCLS: 424/703.000; 514/406.000; 514/473.000; 514/458.000; 514/474.000
NCL NCLM: 424/456.000
NCLS: 424/703.000; 514/406.000; 514/458.000; 514/473.000; 514/474.000
IC [7]
ICM A61K031-415
ICS A61K009-64; A61K031-355; A61K033-04
IPCI A61K0031-415 [ICM,7]; A61K0009-64 [ICS,7]; A61K0009-52 [ICS,7,C*]; A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C*]; A61K0033-04 [ICS,7]
IPCR A61K0009-107 [I,C*]; A61K0009-107 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-64 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-18 [I,C*]; A61K0031-18 [I,A]; A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-63 [I,C*]; A61K0031-635 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 4 USPATFULL on STN
AN 2003:214435 USPATFULL
TI Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
IN Brown, David L., Chesterfield, MO, UNITED STATES
Graneto, Matthew J., Chesterfield, MO, UNITED STATES
Ludwig, Cindy L., St. Louis, MO, UNITED STATES
Molyneaux, John M., St. Louis, MO, UNITED STATES
Talley, John J., Cambridge, MA, UNITED STATES
PA Pharmacia Corporation (U.S. corporation)
PI US 2003149078 A1 20030807
US 6699884 B2 20040302
AI US 2002-319916 A1 20021213 (10)
RLI Continuation of Ser. No. US 2002-124209, filed on 16 Apr 2002, PENDING
PRAI US 2001-285264P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 11198
INCL INCLM: 514/336.000
INCLS: 514/340.000; 514/341.000; 514/374.000; 514/406.000; 514/365.000; 514/397.000; 514/394.000; 514/604.000; 546/269.700; 546/271.400; 546/272.700; 546/275.400; 546/283.400; 546/272.100; 548/202.000; 548/215.000; 548/240.000; 548/304.400; 548/354.100; 548/377.100
NCL NCLM: 514/336.000
NCLS: 514/357.000; 514/408.000; 514/520.000; 514/602.000; 514/709.000; 546/268.100; 546/329.000; 546/330.000; 546/339.000; 548/413.000;

548/577.000; 564/084.000; 564/085.000; 564/086.000; 568/028.000; 568/029.000; 514/340.000; 514/341.000; 514/365.000; 514/374.000; 514/394.000; 514/397.000; 514/406.000; 514/604.000; 546/269.700; 546/271.400; 546/272.100; 546/272.700; 546/275.400; 546/283.400; 548/202.000; 548/215.000; 548/240.000; 548/304.400; 548/354.100; 548/377.100

IC [7]
ICM A61K031-4439
ICS A61K031-4433; A61K031-427; A61K031-422; A61K031-4184; A61K031-4178
IPCI A61K0031-4439 [ICM,7]; A61K0031-4433 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-427 [ICS,7]; A61K0031-422 [ICS,7]; A61K0031-4184 [ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164 [ICS,7,C*]
IPCI-2 A61K0031-40 [ICM,7]; A61K0031-44 [ICS,7]; C07C0317-32 [ICS,7]; C07C0317-00 [ICS,7,C*]; C07D0213-02 [ICS,7]; C07D0213-00 [ICS,7,C*]
IPCR C07D0231-00 [I,C*]; C07D0231-12 [I,A]; C07D0261-00 [I,C*]; C07D0261-08 [I,A]; C07D0307-00 [I,C*]; C07D0307-32 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 4 USPATFULL on STN
AN 2003:45345 USPATFULL
TI Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
IN Brown, David L., Chesterfield, MO, UNITED STATES
Graneto, Matthew J., Chesterfield, MO, UNITED STATES
Ludwig, Cindy L., St. Louis, MO, UNITED STATES
Molyneaux, John M., St. Louis, MO, UNITED STATES
Talley, John J., St. Louis, MO, UNITED STATES
PA Pharmacia Corporation (U.S. corporation)
PI US 2003032657 A1 20030213
US 6673818 B2 20040106
AI US 2002-124209 A1 20020416 (10)
PRAI US 2001-285264P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 11199
INCL INCLM: 514/336.000
INCLS: 514/357.000; 514/408.000; 514/520.000; 514/602.000; 514/709.000; 546/268.100; 546/339.000; 546/329.000; 546/330.000; 548/577.000; 558/413.000; 564/084.000; 564/085.000; 564/086.000; 568/028.000; 568/029.000
NCL NCLM: 514/332.000; 514/336.000
NCLS: 514/277.000; 514/340.000; 514/341.000; 514/357.000; 514/378.000; 514/406.000; 514/438.000; 514/473.000; 514/604.000; 514/703.000; 546/255.000; 546/272.100; 546/272.700; 546/334.000; 546/339.000; 548/247.000; 548/375.100; 548/376.100; 549/059.000; 549/321.000; 549/323.000; 564/090.000; 568/028.000; 514/408.000; 514/520.000; 514/602.000; 514/709.000; 546/268.100; 546/329.000; 546/330.000; 548/577.000; 558/413.000; 564/084.000; 564/085.000; 564/086.000; 568/029.000
IC [7]
ICM A61K031-4439
ICS A61K031-44; A61K031-40; A61K031-277; C07C317-32
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-44 [ICS,7]; A61K0031-40 [ICS,7]; A61K0031-277 [ICS,7]; A61K0031-275 [ICS,7,C*]; C07C0317-32 [ICS,7]; C07C0317-00 [ICS,7,C*]
IPCI-2 C07D0401-02 [ICM,7]; C07D0401-00 [ICM,7,C*]; A61K0031-44 [ICS,7]
IPCR C07D0231-00 [I,C*]; C07D0231-12 [I,A]; C07D0261-00 [I,C*]; C07D0261-08 [I,A]; C07D0307-00 [I,C*]; C07D0307-32 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 23 USPATFULL on STN
TI Stabilized oral pharmaceutical composition
AB An orally deliverable pharmaceutical composition is provided comprising an aminosulfonyl-comprising drug, for example a selective cyclooxygenase-2 inhibitory drug such as celecoxib, and a solvent liquid comprising a polyethylene glycol and one or more free radical-scavenging antioxidants. At least a substantial part of the drug is in dissolved form in the solvent liquid. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders.

ACCESSION NUMBER: 2005:130738 USPATFULL
TITLE: Stabilized oral pharmaceutical composition
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
Huang, Tiehua, Kalamazoo, MI, UNITED STATES
Robins, Russell H., Portage, MI, UNITED STATES
Bauer, Juliane M., Portage, MI, UNITED STATES
Guido, Jane E., Vicksburg, MI, UNITED STATES
Brugger, Andrew M., Libertyville, IL, UNITED STATES
Karim, Aziz, Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005112197	A1	20050526
APPLICATION INFO.:	US 2004-969140	A1	20041020 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-119118, filed on 9 Apr 2002, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284589P	20010417 (60)
	US 2002-357959P	20020219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006, US
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 2122
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 23 USPATFULL on STN
TI Gelatin capsule exhibiting reduced cross-linking
AB The present invention relates to compositions suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced cross-linking, and to methods of preparing such gelatin capsules.

ACCESSION NUMBER: 2004:138713 USPATFULL
TITLE: Gelatin capsule exhibiting reduced cross-linking
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004105885	A1	20040603
APPLICATION INFO.:	US 2003-633194	A1	20030731 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-119129, filed on 9 Apr 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284381P	20010417 (60)
	US 2001-326952P	20011004 (60)

	US 2002-399862P	20020731 (60)
	US 2002-399776P	20020731 (60)
	US 2002-399863P	20020731 (60)
	US 2002-399808P	20020731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1197
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 17 OF 23 USPATFULL on STN
TI Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
AB The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a primary or secondary amine compound in an amount sufficient to inhibit cross-linking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40° C. and 75% relative humidity for a period of 6 months.

ACCESSION NUMBER: 2004:138711 USPATFULL
TITLE: Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
Bauer, Juliane M., Portage, MI, UNITED STATES
He, Xiaorong, Kalamazoo, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004105883	A1	20040603
APPLICATION INFO.:	US 2003-633390	A1	20030731 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-119129, filed on 9 Apr 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284381P	20010417 (60)
	US 2001-326952P	20011004 (60)
	US 2002-399862P	20020731 (60)
	US 2002-399776P	20020731 (60)
	US 2002-399863P	20020731 (60)
	US 2002-399808P	20020731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 20 OF 23 USPATFULL on STN
TI Stabilized oral pharmaceutical composition
AB An orally deliverable pharmaceutical composition is provided comprising an aminosulfonyl-comprising drug, for example a selective cyclooxygenase-2 inhibitory drug such as celecoxib, and a solvent liquid comprising a polyethylene glycol and one or more free radical-scavenging antioxidants. At

least a substantial part of the drug is in dissolved form in the solvent liquid. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders.

ACCESSION NUMBER: 2003:153476 USPATFULL
TITLE: Stabilized oral pharmaceutical composition
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
Huang, Tiehua, Kalamazoo, MI, UNITED STATES
Robins, Russell H., Portage, MI, UNITED STATES
Bauer, Juliane M., Portage, MI, UNITED STATES
Guido, Jane E., Vicksburg, MI, UNITED STATES
Brugger, Andrew M., Libertyville, IL, UNITED STATES
Karim, Aziz, Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003105144	A1	20030605	
APPLICATION INFO.:	US 2002-119118	A1	20020409	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-284589P	20010417	(60)
	US 2002-357959P	20020219	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corporation, Patent Department, 800 N. Lindbergh Boulevard-04E, St. Louis, MO, 63167
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 2152
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 23 OF 23 USPATFULL on STN
TI Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
AB A therapeutic combination useful in the treatment, amelioration, prevention, or delay of pain comprising a high energy form of a selective cyclooxygenase-2 inhibitor, a vasomodulator, and a pharmaceutically acceptable excipient, carrier, or diluent, the cyclooxygenase-2 inhibitor and vasomodulator each being present in an amount effective to contribute to the treatment, prevention, ameloriation or delay of pain.

ACCESSION NUMBER: 2002:149172 USPATFULL
TITLE: Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
INVENTOR(S): Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Skokie, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002077328	A1	20020620	
APPLICATION INFO.:	US 2001-905292	A1	20010713	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-296196P	20010606	(60)
	US 2001-284248P	20010417	(60)
	US 2000-218101P	20000713	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102

NUMBER OF CLAIMS: 125
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 4527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.